Autologous Polyclonal Tregs for Lupus

Inclusion Criteria: * Ability to provide informed consent. * Diagnosis of SLE by American College of Rheumatology (ACR) criteria or biopsy proven primary cutaneous lupus. * Presence of ≥ 2 active cutaneous lupus lesions based on (1) visual morphology and (2) at least a grade 2 erythema on CLASI activity score. Histopathologic confirmation is required unless the active lesions are of the same morphology to previously histologically proven cutaneous lupus lesions. * The cutaneous lupus lesions must include any of the following subtypes: * Acute cutaneous lupus including maculopapular lupus rash and photosensitive lupus rash, * Subacute cutaneous lupus, * Chronic cutaneous lupus including discoid lupus and hypertrophic (verrucous) lupus, * Lupus timidus * Positive test for Epstein-Barr virus (EBV) antibody. * Adequate venous access to support draw of 400 mL whole blood and infusion of investigational therapy. Exclusion Criteria: * New onset of cutaneous lupus which has not been treated with broad spectrum sunscreen (UVA and UVB) in combination with either antimalarials or another systemic medication for at least 3 months. * Prednisone dose \> 15mg/day within the 30 days prior to screening. * Addition of a new medication, or change in the dose of any background medication, used to treat any aspect of SLE. Specifically: * addition or change in systemic glucocorticoids, antimalarials, methotrexate, mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine,…